Stock Track | Travere Therapeutics Plunges 5.09% After-Hours on Mixed Earnings and Insider Selling

Stock Track02-20 05:36

Travere Therapeutics, Inc. (TVTX) experienced a significant after-hours plunge of 5.09% following the release of its fourth quarter and full year 2025 financial results.

The stock's decline appears to be driven by investor reaction to the company's earnings report, which showed strong revenue growth but also revealed an operating loss and a substantial increase in selling, general, and administrative expenses. Additionally, a regulatory filing disclosed that the company's Chief Legal Officer disposed of common shares, which may have contributed to negative sentiment.

Despite reporting a net income of $2.7 million for the quarter and impressive 108% year-over-year growth in U.S. net product sales for its drug FILSPARI, the company posted an operating loss of $32.4 million. The significant rise in SG&A expenses to $101.7 million, attributed to investments for a potential product launch and increased commercialization costs, likely weighed on investor confidence during the after-hours session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111785481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111785481","market":"us","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Plunges 5.09% After-Hours on Mixed Earnings and Insider Selling","media":"Stock Track","content":"<p>Travere Therapeutics, Inc. (TVTX) experienced a significant after-hours plunge of 5.09% following the release of its fourth quarter and full year 2025 financial results.</p><p>The stock's decline appears to be driven by investor reaction to the company's earnings report, which showed strong revenue growth but also revealed an operating loss and a substantial increase in selling, general, and administrative expenses. Additionally, a regulatory filing disclosed that the company's Chief Legal Officer disposed of common shares, which may have contributed to negative sentiment.</p><p>Despite reporting a net income of $2.7 million for the quarter and impressive 108% year-over-year growth in U.S. net product sales for its drug FILSPARI, the company posted an operating loss of $32.4 million. The significant rise in SG&A expenses to $101.7 million, attributed to investments for a potential product launch and increased commercialization costs, likely weighed on investor confidence during the after-hours session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Plunges 5.09% After-Hours on Mixed Earnings and Insider Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Plunges 5.09% After-Hours on Mixed Earnings and Insider Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Travere Therapeutics, Inc. (TVTX) experienced a significant after-hours plunge of 5.09% following the release of its fourth quarter and full year 2025 financial results.</p><p>The stock's decline appears to be driven by investor reaction to the company's earnings report, which showed strong revenue growth but also revealed an operating loss and a substantial increase in selling, general, and administrative expenses. Additionally, a regulatory filing disclosed that the company's Chief Legal Officer disposed of common shares, which may have contributed to negative sentiment.</p><p>Despite reporting a net income of $2.7 million for the quarter and impressive 108% year-over-year growth in U.S. net product sales for its drug FILSPARI, the company posted an operating loss of $32.4 million. The significant rise in SG&A expenses to $101.7 million, attributed to investments for a potential product launch and increased commercialization costs, likely weighed on investor confidence during the after-hours session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1111785481","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111785481","pubTimestamp":1771537008,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Travere Therapeutics, Inc. (TVTX) experienced a significant after-hours plunge of 5.09% following the release of its fourth quarter and full year 2025 financial results.The stock's decline appears to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"个股追踪|Travere Therapeutics盘后暴跌5.09%因盈利好坏参半及内幕抛售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Travere Therapeutics, Inc. (TVTX) experienced a significant after-hours plunge of 5.09% following the release of its fourth quarter and full year 2025 financial results.The stock's decline appears to be driven by investor reaction to the company's earnings report, which showed strong revenue growth but also revealed an operating loss and a substantial increase in selling, general, and administrative expenses. Additionally, a regulatory filing disclosed that the company's Chief Legal Officer disposed of common shares, which may have contributed to negative sentiment.Despite reporting a net income of $2.7 million for the quarter and impressive 108% year-over-year growth in U.S. net product sales for its drug FILSPARI, the company posted an operating loss of $32.4 million. The significant rise in SG&A expenses to $101.7 million, attributed to investments for a potential product launch and increased commercialization costs, likely weighed on investor confidence during the after-hours session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111785481","isCrawlerRequest":true}